Related Experiment Video
Updated: Apr 24, 2026
Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care
Published on: February 16, 2015
Immunotherapy advances for glioblastoma
David A Reardon1, Gordon Freeman1, Catherine Wu1
1Center for Neuro-Oncology, Dana-Farber/Brigham and Women's Cancer Center, Boston, Massachusetts (D.A.R., P.Y.W.); Department of Cancer Immunology and AIDS, Dana-Farber Cancer Institute, Boston, Massachusetts (G.F., C.W., K.W.W.); Department of Medical Oncology, Dana-Farber/Brigham and Women's Cancer Center, Boston, Massachusetts (D.A.R., C.W.); Department of Neurosurgery, Brigham and Women's Hospital, Boston, Massachusetts (E.A.C.); Division of Neuro-Oncology, Department of Neurology, Brigham and Women's Hospital, Boston, Massachusetts (P.Y.W.); Division of Neurosurgery, Department of Surgery, Duke University Medical Center, Durham, North Carolina (J.H.S.); Department of Neurosurgery, Massachusetts General Hospital, Boston, Massachusetts (W.T.C.); Department of Medical Oncology and Cancer Vaccine Center, Dana-Farber/Brigham and Women's Cancer Center, Boston, Massachusetts (C.W., E.F.F., G.D.); Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts (G.D.).
Abstract:
Survival for patients with glioblastoma, the most common high-grade primary CNS tumor, remains poor despite multiple therapeutic interventions including intensifying cytotoxic therapy, targeting dysregulated cell signaling pathways, and blocking angiogenesis. Exciting, durable clinical benefits have recently been demonstrated for a number of other challenging cancers using a variety of immunotherapeutic approaches. Much modern research confirms that the CNS is immunoactive rather than immunoprivileged. Preliminary results of clinical studies demonstrate that varied vaccine strategies have achieved encouraging evidence of clinical benefit for glioblastoma patients, although multiple variables will likely require systematic investigation before optimal outcomes are realized. Initial preclinical studies have also revealed promising results with other immunotherapies including cell-based approaches and immune checkpoint blockade. Clinical studies to evaluate a wide array of immune therapies for malignant glioma patients are being rapidly developed. Important considerations going forward include optimizing response assessment and identifiying correlative biomarkers for predict therapeutic benefit. Finally, the potential of complementary combinatorial immunotherapeutic regimens is highly exciting and warrants expedited investigation.
Insights
Immunotherapy offers new hope for glioblastoma (a type of brain cancer) patients, showing promising early results with vaccines and other approaches. Further research is needed to optimize these treatments for better outcomes.
Area of Science:
- Neuro-oncology
- Cancer immunotherapy
- Central nervous system (CNS) research
Background:
- Glioblastoma, a primary CNS tumor, has poor survival rates despite current treatments.
- The central nervous system is increasingly recognized as an active immune environment.
- Recent successes in other cancers highlight the potential of immunotherapy.
Purpose of the Study:
- To review the emerging role of immunotherapy in treating glioblastoma.
- To discuss preliminary findings from vaccine and other immunotherapeutic strategies.
- To identify key considerations for future clinical development.
Main Methods:
- Review of preliminary clinical and preclinical data on immunotherapies for glioblastoma.
- Analysis of vaccine strategies, cell-based therapies, and immune checkpoint blockade.
- Consideration of response assessment and biomarker identification.
Main Results:
- Vaccine strategies show encouraging clinical benefit in early glioblastoma studies.
- Preclinical data suggest promise for cell-based therapies and immune checkpoint inhibitors.
- Optimizing treatment variables and assessment methods is crucial.
Conclusions:
- Immunotherapy, including vaccines and checkpoint blockade, presents a promising frontier for glioblastoma treatment.
- Systematic investigation and biomarker identification are essential for realizing optimal outcomes.
- Combinatorial immunotherapeutic regimens warrant expedited research.
More Related Videos
11:15Stereotactic Adoptive Transfer of Cytotoxic Immune Cells in Murine Models of Orthotopic Human Glioblastoma Multiforme Xenografts
Published on: September 1, 2018
06:15Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
Published on: October 27, 2014
Related Concept Videos
01:27Tumor Immunotherapy
01:30Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...